Marwa Noueihad1,
Tariq Ali Elhassan2,
Waad Alrohily3,
Sarah A Fatani3,
Riham Mohamed Elshafie3,4,
Syed Wasif Gillani5 
For correspondence:- Syed Gillani Email: dr.syedwasif@gmu.ac.ae Tel:+971509577406
Received: 28 October 2025 Accepted: 15 May 2026 Published: 31 May 2026
Citation: Noueihad M, Elhassan TA, Alrohily W, Fatani SA, Elshafie RM, Gillani SW. Influence of dual metabolic modulation with ranolazine and trimetazidine on post-operative outcomes in CABG patients: A retrospective cohort study. Trop J Pharm Res 2026; 25(5):715-722 doi: https://dx.doi.org/10.4314/tjpr.v25i5.13
© 2026 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To investigate post-operative complications of coronary artery bypass grafting (CABG) with ranolazine and trimetazidine compared to conventional guideline-directed therapy among coronary artery disease patients in a tertiary hospital. Methods: A total of 181 (78.69 %) patients from 230 (underwent CABG surgery) were enrolled to evaluate the outcome. These patients received ranolazine (200 mg twice daily orally) and trimetazidine (35 mg twice daily) along with conventional guideline-directed therapy during perioperative hospitalization. The outcomes and readmission rate with the interventional therapy were compared up to 3 months after surgery. Results: Mean age was 53.2 ± 7.5 years, gender distribution was predominantly male (96.1 %). Hypertension was the highest comorbidity (85.7 %). Post-operative complications were recorded in 131(72.4 %) of patients. Age, body mass index (BMI), hypertension (HTN), and hyperlipidemia (HLD) showed no significant relationship with incidence of post-operative complications (p > 0.05). Furthermore, type 2 diabetes mellitus (T2DM) was significantly associated with post-operative complications (p < 0.05). During the 3-month follow-up, a total of 29(16 %) patients were readmitted of which 22(75.9 %) who experienced post-operative complications were again readmitted compared to 7(24.1 %) who did not experience complications. Conclusion: Adjunct therapy demonstrates no significant clinical effect on either post-operative complications or rate of readmissions in CABG patients. Further multicenter randomized clinical trials are required to evaluate the efficacy and safety of adjunct therapies.
Fulltext in PDF